Stay updated on Cediranib+Olaparib vs Other Treatments in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Cediranib+Olaparib vs Other Treatments in Ovarian Cancer Clinical Trial page.

Latest updates to the Cediranib+Olaparib vs Other Treatments in Ovarian Cancer Clinical Trial page
- Check6 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page header/footer.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedMinor administrative updates: the page revision is updated to v3.4.2 and the previous funding/status notices are removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedNotices about government funding lapse and NIH operating status were added, and the page version was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedUI updates include showing the glossary option, adding the label 'Last Update Submitted that Met QC Criteria,' capitalization adjustment for 'No FEAR Act Data,' and a new revision reference (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated to v3.3.4 (replacing the previous v3.3.3) on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a Locations section listing Pennsylvania as the study site; removed the separate 'Pennsylvania Locations' entry and updated the page revision to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Cediranib+Olaparib vs Other Treatments in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cediranib+Olaparib vs Other Treatments in Ovarian Cancer Clinical Trial page.